News
Dear C.D.: It seems to me that we humans have a protective mechanism that lets us forget just how sick we were when we had ...
Three Motley Fool contributors think they've found no-brainer healthcare stocks to buy in May. Here's why they picked Eli ...
Sometimes, it makes sense to skip insurance and instead take advantage of a health savings account or flexible savings ...
Viking Therapeutics (NASDAQ: VKTX), a biotech that has shot to prominence thanks to a weight-loss drug it is developing, was ...
NEW YORK (AP) — More U.S. children have died this flu season than at any time since the swine flu pandemic 15 years ago, according to a federal report released Friday. The 216 pediatric deaths ...
Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...
Tim Friede has been bitten by snakes hundreds of times — often on purpose. Now scientists are studying his blood in hopes of ...
Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep medicine.
In an internal memo, the World Health Organization signaled its support for anti-obesity drugs like Wegovy and Zepbound, ...
Medicare kickbacks alleged, Joann store closures, and more business headlines. Read the latest news and updates here.
With Wegovy in its portfolio, Novo Nordisk is a very good bet to continue being a winner. As it's currently considered something of an underdog, with its stock priced accordingly, it's also trading at ...
CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results